<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302483</url>
  </required_header>
  <id_info>
    <org_study_id>SR 2-01</org_study_id>
    <nct_id>NCT01302483</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia</brief_title>
  <official_title>A Phase II, Single-Center, Randomized, Double-Blind, Active-Treatment-Controlled, Parallel-Group Study of the Efficacy of Kovacaine Nasal Spray for Anesthetizing Maxillary Teeth in Healthy Dental Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Renatus, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ground Zero Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rho, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Renatus, LLC</source>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the safety and efficacy of Kovacaine Mist (3%
      tetracaine HCl with 0.05% oxymetazoline HCl) for anesthesia of the maxillary teeth for dental
      procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this single-center, randomized, double-blind, active-controlled,
      parallel-group study was to determine if Kovacaine Mist provided anesthesia of the maxillary
      teeth sufficient for the performance of dental procedures. Secondary objectives included a
      determination of whether Kovacaine Mist provided anesthesia of the soft tissue and to
      evaluate the safety and tolerability of Kovacaine Mist and sham injection as compared to sham
      nasal spray and 2% lidocaine hydrochloride with 1:100,000 epinephrine submucosal injection
      and as determined by changes in vital signs and reports of side effects and adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulpal Anesthesia</measure>
    <time_frame>Continuous throughout dental treatment period (up to 60 minutes)</time_frame>
    <description>Number of participants who did not need rescue anesthesia to complete the study dental procedure, i.e. Kovacaine provided enough pulpal anesthesia to complete a dental procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Soft Tissue Anesthesia Duration</measure>
    <time_frame>Baseline, 15, 20, 30, 40, 50, 60, 80, 100, 120 minutes</time_frame>
    <description>Assessment of pain using a Rotadent sensor probe, applying up to 20 grams/cm^2 at the tissue site. At each time point, participants were asked if they felt pain from the sensor probe at each site location in the mouth. The four sites were:
Site 1: Distal to the apex of the tooth in the position of the maxillary first premolar at the deepest point in the buccal vestibule
Site 2: Apical to the maxillary lateral incisor at the deepest point in the labial vestibule
Site 3: Incisive papilla
Site 4: At the confluence of the alveolar process and hard palate medial to the maxillary second premolar (near the greater palatine foramen)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Change in Pulse From Baseline</measure>
    <time_frame>Baseline, 15, 20, 30, 40, 50, 60, 120 minutes</time_frame>
    <description>Maximum change from Baseline at any time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Change in Blood Pressure From Baseline</measure>
    <time_frame>Baseline, 15, 20, 30, 40 50, 60, 120 minutes</time_frame>
    <description>Maximum change from Baseline at any time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Change in Pulse Oximetry From Baseline</measure>
    <time_frame>Baseline, 15, 20, 30, 40, 50, 60, 120 minutes</time_frame>
    <description>Maximum change from Baseline at any time point</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Dental Anesthesia Efficacy</condition>
  <arm_group>
    <arm_group_label>Kovacaine Nasal Spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3% tetracaine HCL with 0.05% oxymetazoline HCL - Delivered via 3 sprays (100 uL) in each nostril</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lidocaine Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>.5 to 1 catridge of 2% lidocaine HCL with 1:100,000 epinephrine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% tetracaine HCL with 0.05% oxymetazoline HCL</intervention_name>
    <description>1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.</description>
    <arm_group_label>Kovacaine Nasal Spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Injection</intervention_name>
    <description>Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.</description>
    <arm_group_label>Lidocaine Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 18 and 65 years of age

          -  Sufficiently healthy as determined by the investigator to receive the test and control
             medications and undergo the scheduled dental procedure

          -  Required an operative restorative procedure on a single maxillary tooth, other than a
             maxillary second or third molar, with treatment time not expected to exceed 60 minutes

          -  Could breathe through both nostrils

          -  Had normal lip, nose, eyelid, and cheek sensations

          -  Could understand and sign the informed consent document

          -  Could communicate with the investigator

          -  Could understand and comply with the requirements of the protocol

        Exclusion Criteria:

          -  Clinically relevant history or presence of respiratory, gastrointestinal, renal,
             hepatic, hematological, lymphatic, cardiovascular, psychiatric, musculoskeletal,
             neurologic, genitourinary, infective, inflammatory, immunological, dermatological, or
             connective tissue disease or disorder or a clinically relevant history or presence of
             angle-closure glaucoma

          -  Clinically relevant sinus/nasal surgical history

          -  Baseline Visual Analog Scale value of &gt; 36 (or greater than weak) at the treatment
             site

          -  Had not had dental work requiring a local anesthetic within the last 24 hours or had
             taken pain medications within the last 48 hours

          -  Required prophylactic antibiotics for subacute bacterial endocarditis (infectious
             endocarditis)

          -  Allergic to or intolerant of tetracaine, benzocaine, other ester local anesthetics, or
             p-aminobenzoic acid (PABA), as found in PABA-containing sunscreens

          -  Allergic to or intolerant of oxymetazoline, epinephrine, or preservatives in their
             solutions

          -  Had a current condition, such as nasal congestion or sinus infection, that may have
             influenced responses to study medications

          -  History of alcoholism and/or drug abuse

          -  Had taken a monamine oxidase inhibitor within the past 3 weeks

          -  Were nursing, pregnant, suspected of being pregnant, or trying to become pregnant
             (females were required to take a urine pregnancy test to rule out pregnancy)

          -  Had used any investigational drug and/or participated in any clinical trial within 30
             days of baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sebastian G Ciancio, DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Periodontics &amp; Endodontics, School of Dental Medicine, University at Buffalo, SUNY</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <results_first_submitted>March 2, 2011</results_first_submitted>
  <results_first_submitted_qc>June 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 17, 2015</results_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Tetracaine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylephrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment completed within the month of December, 2008. Subjects were primarily recruited from University of Buffalo staff and students.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Kovacaine Nasal Spray</title>
          <description>.6mL 3% tetracaine HCL with 0.05% oxymetazoline HCL</description>
        </group>
        <group group_id="P2">
          <title>Lidocaine Injection</title>
          <description>2% lidocaine HCL with 1:100,000 epinephrine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Kovacaine Nasal Spray</title>
        </group>
        <group group_id="B2">
          <title>Lidocaine Injection</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="12.8"/>
                    <measurement group_id="B2" value="40.8" spread="15.3"/>
                    <measurement group_id="B3" value="39.3" spread="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pulpal Anesthesia</title>
        <description>Number of participants who did not need rescue anesthesia to complete the study dental procedure, i.e. Kovacaine provided enough pulpal anesthesia to complete a dental procedure.</description>
        <time_frame>Continuous throughout dental treatment period (up to 60 minutes)</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Number of subjects able to complete the dental procedure without rescue</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>Number of subjects able to complete the dental procedure without rescue</description>
          </group>
        </group_list>
        <measure>
          <title>Pulpal Anesthesia</title>
          <description>Number of participants who did not need rescue anesthesia to complete the study dental procedure, i.e. Kovacaine provided enough pulpal anesthesia to complete a dental procedure.</description>
          <population>Intention to treat</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soft Tissue Anesthesia Duration</title>
        <description>Assessment of pain using a Rotadent sensor probe, applying up to 20 grams/cm^2 at the tissue site. At each time point, participants were asked if they felt pain from the sensor probe at each site location in the mouth. The four sites were:
Site 1: Distal to the apex of the tooth in the position of the maxillary first premolar at the deepest point in the buccal vestibule
Site 2: Apical to the maxillary lateral incisor at the deepest point in the labial vestibule
Site 3: Incisive papilla
Site 4: At the confluence of the alveolar process and hard palate medial to the maxillary second premolar (near the greater palatine foramen)</description>
        <time_frame>Baseline, 15, 20, 30, 40, 50, 60, 80, 100, 120 minutes</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Duration of Soft Tissue Anesthesia</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>Duration of Soft Tissue Anesthesia</description>
          </group>
        </group_list>
        <measure>
          <title>Soft Tissue Anesthesia Duration</title>
          <description>Assessment of pain using a Rotadent sensor probe, applying up to 20 grams/cm^2 at the tissue site. At each time point, participants were asked if they felt pain from the sensor probe at each site location in the mouth. The four sites were:
Site 1: Distal to the apex of the tooth in the position of the maxillary first premolar at the deepest point in the buccal vestibule
Site 2: Apical to the maxillary lateral incisor at the deepest point in the labial vestibule
Site 3: Incisive papilla
Site 4: At the confluence of the alveolar process and hard palate medial to the maxillary second premolar (near the greater palatine foramen)</description>
          <population>Intention to treat</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Site 1 Duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1" spread="16.9"/>
                    <measurement group_id="O2" value="34.2" spread="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Site 2 Duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.1" spread="16.9"/>
                    <measurement group_id="O2" value="32.1" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Site 3 Duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8" spread="19.9"/>
                    <measurement group_id="O2" value="25.0" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Site 4 Duration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.4" spread="24.1"/>
                    <measurement group_id="O2" value="29.3" spread="27.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Change in Pulse From Baseline</title>
        <description>Maximum change from Baseline at any time point.</description>
        <time_frame>Baseline, 15, 20, 30, 40, 50, 60, 120 minutes</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>.6mL 3% tetracaine HCL with 0.05% oxymetazoline HCL</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>2% lidocaine HCL with 1:100,000 epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Change in Pulse From Baseline</title>
          <description>Maximum change from Baseline at any time point.</description>
          <population>Intention to treat</population>
          <units>beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.13" spread="9.68"/>
                    <measurement group_id="O2" value="-6.60" spread="15.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Change in Blood Pressure From Baseline</title>
        <description>Maximum change from Baseline at any time point.</description>
        <time_frame>Baseline, 15, 20, 30, 40 50, 60, 120 minutes</time_frame>
        <population>Intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>Blood Pressure Maximum Change from Baseline</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>Blood Pressure Maximum Change from Baseline</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Change in Blood Pressure From Baseline</title>
          <description>Maximum change from Baseline at any time point.</description>
          <population>Intention to treat</population>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.50" spread="17.39"/>
                    <measurement group_id="O2" value="3.43" spread="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.67" spread="13.73"/>
                    <measurement group_id="O2" value="-5.07" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Change in Pulse Oximetry From Baseline</title>
        <description>Maximum change from Baseline at any time point</description>
        <time_frame>Baseline, 15, 20, 30, 40, 50, 60, 120 minutes</time_frame>
        <population>Intent to Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Kovacaine Nasal Spray</title>
            <description>.6mL 3% tetracaine HCL with 0.05% oxymetazoline HCL</description>
          </group>
          <group group_id="O2">
            <title>Lidocaine Injection</title>
            <description>2% lidocaine HCL with 1:100,000 epinephrine</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Change in Pulse Oximetry From Baseline</title>
          <description>Maximum change from Baseline at any time point</description>
          <population>Intent to Treat</population>
          <units>SpO2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="2.39"/>
                    <measurement group_id="O2" value="-0.80" spread="2.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Kovacaine Nasal Spray</title>
          <description>.6mL 3% tetracaine HCL with 0.05% oxymetazoline HCL</description>
        </group>
        <group group_id="E2">
          <title>Lidocaine Injection</title>
          <description>2% lidocaine HCL with 1:100,000 epinephrine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The VAS was misadministered such that even subjects with enough pain to require rescue reported essentially no pain on the global VAS. As this would exaggerate the efficacy of the study drug, these measures were not used to calculate its efficacy.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sebastian Ciancio</name_or_title>
      <organization>Department of Periodontics &amp; Endodontics, School of Dental Medicine, University of Buffalo, SUNY</organization>
      <phone>(716) 829-3848</phone>
      <email>ciancio@buffalo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

